Mainz, Germany, March 23, 2021 (GLOBE NEWSWIRE) -- 
https://www.globenewswire.com/Tracker?data=E-kmH4sg6mFLyAQy9Hp8AMfoAzx_58hZ6kUwaliduV1aEI_Po0hvm5Yq8FVagmmAmdK7Zp3WTLYgnBZO5NR2EA== 
BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") will announce 
its financial results for the fourth quarter 2020 on Tuesday, March 
30(th) , 2021. BioNTech invites investors and the general public to join 
a conference call and webcast with investment analysts on the same day 
at 8.00 a.m. EDT (2.00 p.m. CET) to report its financial results and 
provide a corporate update on the fourth quarter and full year 2020. 
 
   The slide presentation and audio of the webcast will be available via 
the following link: 
https://www.globenewswire.com/Tracker?data=yQiGRKh2kVNv4AFdSx62heaDV7rbfqLgMoLQpdFWZTPzkI2qkmtwEIobDQdaIMg1CmfBX6JtCCHNQqi5sVeeqDSSw2UGeWuJyGYg_w5TaelNBGxvmCvCEo7wNKQ2wUzGT3cRA5z0CITISq9yYi2KlQ== 
https://edge.media-server.com/mmc/p/j78pn8zg 
 
   To participate in the conference call, please dial the following numbers 
ten minutes prior to the start and provide the Conference ID: 
 
 
 
 
United States international:  +1 646 741 3167 
 United States domestic        +1 877 870 9135 
 (toll-free):                  +49 (0) 692 2222 625 
 Germany:                      4038477 
 Conference ID: 
 
 
   Participants may also access the slides and the webcast of the 
conference call via the "Events & Presentations" page of the Investor 
Relations section of the Company's website at 
https://www.globenewswire.com/Tracker?data=yQiGRKh2kVNv4AFdSx62haeh3hhCretc4uDBGYCN6QUuiWLP-fWQp8VCCWFhGaHG2OyPu7fQg833heiL3QjQqw== 
https://biontech.de/. A replay of the webcast will be available shortly 
after the conclusion of the call and archived on the Company's website 
for 30 days following the call. 
 
   About BioNTech 
 
   Biopharmaceutical New Technologies is a next generation immunotherapy 
company pioneering novel therapies for cancer and other serious 
diseases. The Company exploits a wide array of computational discovery 
and therapeutic drug platforms for the rapid development of novel 
biopharmaceuticals. Its broad portfolio of oncology product candidates 
includes individualized and off-the-shelf mRNA-based therapies, 
innovative chimeric antigen receptor T cells, bi-specific checkpoint 
immuno-modulators, targeted cancer antibodies and small molecules. Based 
on its deep expertise in mRNA vaccine development and in-house 
manufacturing capabilities, BioNTech and its collaborators are 
developing multiple mRNA vaccine candidates for a range of infectious 
diseases alongside its diverse oncology pipeline. BioNTech has 
established a broad set of relationships with multiple global 
pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal 
Health, Genentech, a member of the Roche Group, Regeneron, Genevant, 
Fosun Pharma, and Pfizer. 
 
   For more information, please visit 
https://www.globenewswire.com/Tracker?data=seey_9wdPCicKzsLPss6ElkOSihi8KisjNmwjxuhNTZt0268_8NI7EHWrA7K47GKglwRZuXP6HFu8d6NUcIXAg== 
www.BioNTech.de. 
 
   BioNTech Contacts 
 
   Investor Relations 
 
   Sylke Maas, Ph.D. 
 
   +49 (0)6131 9084 1074 
 
   https://www.globenewswire.com/Tracker?data=YmALxxvlfzbrTX46L8u_MrVBjrxHko9kzV5R39ey1D3DN3zdkeVtmKM0rgaQalLGcjFRCz_KzxwgwOHqEdrQcVbTDlP3brcW_gctM61rN_4= 
Investors@biontech.de 
 
   Media Relations 
 
   Jasmina Alatovic 
 
   +49 (0)6131 9084 1513 
 
   https://www.globenewswire.com/Tracker?data=TmVqa5DEAPCkfhfZ6QPGlZBKgXHECDlTHGseKDOJQXgbjwMxVYTeQTlwHKACPS0ZOw80Zr2AAbz33JI5JXlG2xNKEOBrpOICErzfZ03nUfA= 
Media@biontech.de

(END) Dow Jones Newswires

March 23, 2021 07:00 ET (11:00 GMT)